经颈静脉肝内门体分流术在肝硬化食管胃底静脉曲张破裂出血中的应用现状与未来展望

吕勇; 樊代明; 韩国宏

doi:10.3969/j.issn.1001-5256.2022.06.004

经颈静脉肝内门体分流术在肝硬化食管胃底静脉曲张破裂出血中的应用现状与未来展望

DOI: 10.3969/j.issn.1001-5256.2022.06.004

吕勇^{1, 2},
樊代明¹,
韩国宏^3, , ,

1.
空军军医大学西京医院消化内科，西安 710032
2.
空军军医大学军事医学创新中心，西安 710032
3.
西安国际医学中心医院消化病医院消化介入科，西安 710100

利益冲突声明: 所有作者均声明不存在利益冲突。

作者贡献声明: 吕勇负责撰写文章；韩国宏、樊代明指导文章撰写及最后定稿。

详细信息

通信作者:
韩国宏，13991969930@126.com

计量
- 文章访问数: 802
- HTML全文浏览量: 202
- PDF下载量: 199
- 被引次数: 0
出版历程
- 收稿日期: 2022-05-01
- 录用日期: 2022-06-02
- 出版日期: 2022-06-20

Application status and future prospect of transjugular intrahepatic portosystemic shunt in gastroesophageal variceal bleeding in liver cirrhosis

Yong LYU^{1, 2},
Daiming FAN¹,
Guohong HAN^{3
, ,
,}

1.
Department of Gastroenterology, Xijing Hospital, Air Force Medical University, Xi'an 710032, China
2.
Military Medical Innovation Center, Air Force Medical University, Xi'an 710032, China
3.
Department of Digestive Intervention, Digestive Diseases Hospital, Xi'an International Medical Center Hospital, Xi'an 710100, China

More Information

Corresponding author: HAN Guohong, 13991969930@126.com (ORCID: 0000-0003-4568-3776)

摘要

摘要: 食管胃底静脉曲张破裂出血是肝硬化门静脉高压的致命性并发症。经颈静脉肝内门体分流术(TIPS)是治疗门静脉高压并发症的有效手段。TIPS可用于预防复发性或顽固性腹水患者的首次静脉曲张出血。对急性静脉曲张出血高危(Child-Pugh C级＜14分、Child-Pugh B级＞7分伴内镜下活动性出血或肝静脉压力梯＞20 mmHg)的患者，应当尽早行TIPS治疗。对标准治疗失败的急性静脉曲张出血，TIPS是有效的挽救措施。此外，TIPS也是预防静脉曲张再出血的二线选择。
- 肝硬化 /
- 门静脉高压 /
- 门体分流术，经颈静脉肝内 /
- 食管和胃静脉曲张
Abstract: Gastroesophageal variceal bleeding is the life-threating complication of cirrhotic portal hypertension, and transjugular intrahepatic portosystemic shunt (TIPS) is an effective therapy for portal hypertension-related complications. TIPS can be used for the prevention of first-time bleeding in patients with recurrent or intractable ascites. TIPS should be performed as early as possible for patients at a high risk of acute variceal bleeding (Child-Pugh class C < 14 points or Child-Pugh class B > 7 points with active bleeding on endoscopy or hepatic venous pressure > 20 mmHg). TIPS is an effective salvage therapy for acute variceal bleeding with failure after standard treatment, and is also a second-line option for preventing variceal rebleeding.
- Liver Cirrhosis /
- Portal Hypertension /
- Portasystemic Shunt, Transjugular Intrahepatic /
- Esophageal and Gastric Varices

HTML全文

参考文献(44)

[1]	GARCIA-TSAO G, BOSCH J. Management of varices and variceal hemorrhage in cirrhosis[J]. N Engl J Med, 2010, 362(9): 823-832. DOI: 10.1056/NEJMra0901512.
[2]	HERNÁNDEZ-GEA V, BERBEL C, BAIGES A, et al. Acute variceal bleeding: risk stratification and management (including TIPS)[J]. Hepatol Int, 2018, 12(Suppl 1): 81-90. DOI: 10.1007/s12072-017-9804-3.
[3]	TRIPATHI D, STANLEY AJ, HAYES PC, et al. Transjugular intrahepatic portosystemic stent-shunt in the management of portal hypertension[J]. Gut, 2020, 69(7): 1173-1192. DOI: 10.1136/gutjnl-2019-320221.
[4]	LYU Y, HAN GH, FAN DM. Transjugular intrahepatic portosystemic shunt for esophagogastric variceal bleeding in liver cirrhosis: intended population and timing[J]. Chin J Hepatol, 2017, 25(6): 402-407. DOI: 10.3760/cma.j.issn.1007-3418.2017.06.002. 吕勇, 韩国宏, 樊代明. 经颈内静脉肝内门体分流术治疗肝硬化食管胃静脉曲张出血的最适人群和时机[J]. 中华肝脏病杂志, 2017, 25(6): 402-407. DOI: 10.3760/cma.j.issn.1007-3418.2017.06.002.
[5]	European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis[J]. J Hepatol, 2018, 69(2): 406-460. DOI: 10.1016/j.jhep.2018.03.024.
[6]	GARCIA-TSAO G, ABRALDES JG, BERZIGOTTI A, et al. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases[J]. Hepatology, 2017, 65(1): 310-335. DOI: 10.1002/hep.28906.
[7]	de FRANCHIS R, BOSCH J, GARCIA-TSAO G, et al. Baveno Ⅶ - Renewing consensus in portal hypertension[J]. J Hepatol, 2022, 76(4): 959-974. DOI: 10.1016/j.jhep.2021.12.022.
[8]	BUREAU C, THABUT D, OBERTI F, et al. Transjugular intrahepatic portosystemic shunts with covered stents increase transplant-free survival of patients with cirrhosis and recurrent ascites[J]. Gastroenterology, 2017, 152(1): 157-163. DOI: 10.1053/j.gastro.2016.09.016.
[9]	VANGELI M, PATCH D, BURROUGHS AK. Salvage tips for uncontrolled variceal bleeding[J]. J Hepatol, 2002, 37(5): 703-704. DOI: 10.1016/s0168-8278(02)00321-5.
[10]	BOUZBIB C, CLUZEL P, SULTANIK P, et al. Prognosis of patients undergoing salvage TIPS is still poor in the preemptive TIPS era[J]. Clin Res Hepatol Gastroenterol, 2021, 45(6): 101593. DOI: 10.1016/j.clinre.2020.101593.
[11]	MAIMONE S, SAFFIOTI F, FILOMIA R, et al. Predictors of re-bleeding and mortality among patients with refractory variceal bleeding undergoing salvage transjugular intrahepatic portosystemic shunt (TIPS)[J]. Dig Dis Sci, 2019, 64(5): 1335-1345. DOI: 10.1007/s10620-018-5412-x.
[12]	WALTER A, RUDLER M, OLIVAS P, et al. Combination of model for end-stage liver disease and lactate predicts death in patients treated with salvage transjugular intrahepatic portosystemic shunt for refractory variceal bleeding[J]. Hepatology, 2021, 74(4): 2085-2101. DOI: 10.1002/hep.31913.
[13]	RUDLER M, ROUSSEAU G, THABUT D. Salvage transjugular intrahepatic portosystemic shunt followed by early transplantation in patients with Child C14-15 cirrhosis and refractory variceal bleeding: a strategy improving survival[J]. Transpl Int, 2013, 26(6): E50-E51. DOI: 10.1111/tri.12090.
[14]	KUMAR R, KERBERT A, SHEIKH MF, et al. Determinants of mortality in patients with cirrhosis and uncontrolled variceal bleeding[J]. J Hepatol, 2021, 74(1): 66-79. DOI: 10.1016/j.jhep.2020.06.010.
[15]	GARCÍA-PAGÁN JC, SAFFO S, MANDORFER M, et al. Where does TIPS fit in the management of patients with cirrhosis?[J]. JHEP Rep, 2020, 2(4): 100122. DOI: 10.1016/j.jhepr.2020.100122.
[16]	MONESCILLO A, MARTÍNEZ-LAGARES F, RUIZ-DEL-ARBOL L, et al. Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding[J]. Hepatology, 2004, 40(4): 793-801. DOI: 10.1002/hep.20386.
[17]	GARCÍA-PAGÁN JC, CACA K, BUREAU C, et al. Early use of TIPS in patients with cirrhosis and variceal bleeding[J]. N Engl J Med, 2010, 362(25): 2370-2379. DOI: 10.1056/NEJMoa0910102.
[18]	RUDLER M, CLUZEL P, CORVEC TL, et al. Early-TIPSS placement prevents rebleeding in high-risk patients with variceal bleeding, without improving survival[J]. Aliment Pharmacol Ther, 2014, 40(9): 1074-1080. DOI: 10.1111/apt.12934.
[19]	GARCIA-PAGÁN JC, DI PASCOLI M, CACA K, et al. Use of early-TIPS for high-risk variceal bleeding: results of a post-RCT surveillance study[J]. J Hepatol, 2013, 58(1): 45-50. DOI: 10.1016/j.jhep.2012.08.020.
[20]	THABUT D, PAUWELS A, CARBONELL N, et al. Cirrhotic patients with portal hypertension-related bleeding and an indication for early-TIPS: a large multicentre audit with real-life results[J]. J Hepatol, 2017, 68(1): 73-81. DOI: 10.1016/j.jhep.2017.09.002.
[21]	de FRANCHIS R, Baveno V Faculty. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension[J]. J Hepatol, 2010, 53(4): 762-768. DOI: 10.1016/j.jhep.2010.06.004.
[22]	de FRANCHIS R, Baveno VI Faculty. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension[J]. J Hepatol, 2015, 63(3): 743-752. DOI: 10.1016/j.jhep.2015.05.022.
[23]	HERNÁNDEZ-GEA V, PROCOPET B, GIRÁLDEZÁ, et al. Preemptive-TIPS improves outcome in high-risk variceal bleeding: an observational study[J]. Hepatology, 2019, 69(1): 282-293. DOI: 10.1002/hep.30182.
[24]	LV Y, YANG Z, LIU L, et al. Early TIPS with covered stents versus standard treatment for acute variceal bleeding in patients with advanced cirrhosis: a randomised controlled trial[J]. Lancet Gastroenterol Hepatol, 2019, 4(8): 587-598. DOI: 10.1016/S2468-1253(19)30090-1.
[25]	DUNNE P, SINHA R, STANLEY AJ, et al. Randomised clinical trial: standard of care versus early-transjugular intrahepatic porto-systemic shunt (TIPSS) in patients with cirrhosis and oesophageal variceal bleeding[J]. Aliment Pharmacol Ther, 2020, 52(1): 98-106. DOI: 10.1111/apt.15797.
[26]	AUGUSTIN S, ALTAMIRANO J, GONZÁLEZ A, et al. Effectiveness of combined pharmacologic and ligation therapy in high-risk patients with acute esophageal variceal bleeding[J]. Am J Gastroenterol, 2011, 106(10): 1787-1795. DOI: 10.1038/ajg.2011.173.
[27]	CONEJO I, GUARDASCIONE MA, TANDON P, et al. Multicenter external validation of risk stratification criteria for patients with variceal bleeding[J]. Clin Gastroenterol Hepatol, 2018, 16(1): 132-139. e8. DOI: 10.1016/j.cgh.2017.04.042.
[28]	RUDLER M, BUREAU C, CARBONELL N, et al. Recalibrated MELD and hepatic encephalopathy are prognostic factors in cirrhotic patients with acute variceal bleeding[J]. Liver Int, 2018, 38(3): 469-476. DOI: 10.1111/liv.13632.
[29]	REVERTER E, TANDON P, AUGUSTIN S, et al. A MELD-based model to determine risk of mortality among patients with acute variceal bleeding[J]. Gastroenterology, 2014, 146(2): 412-419. e3. DOI: 10.1053/j.gastro.2013.10.018.
[30]	LV Y, ZUO L, ZHU X, et al. Identifying optimal candidates for early TIPS among patients with cirrhosis and acute variceal bleeding: a multicentre observational study[J]. Gut, 2019, 68(7): 1297-1310. DOI: 10.1136/gutjnl-2018-317057.
[31]	NICOARǍ-FARCǍU O, HAN G, RUDLER M, et al. Effects of early placement of transjugular portosystemic shunts in patients with high-risk acute variceal bleeding: a meta-analysis of individual patient data[J]. Gastroenterology, 2021, 160(1): 193-205. e10. DOI: 10.1053/j.gastro.2020.09.026.
[32]	LV Y, WANG Z, LI K, et al. Risk stratification based on chronic liver failure consortium acute decompensation score in patients with Child-Pugh B cirrhosis and acute variceal bleeding[J]. Hepatology, 2021, 73(4): 1478-1493. DOI: 10.1002/hep.31478.
[33]	TREBICKA J, GU W, IBÁÑEZ-SAMANIEGO L, et al. Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS[J]. J Hepatol, 2020, 73(5): 1082-1091. DOI: 10.1016/j.jhep.2020.04.024.
[34]	SAUERBRUCH T, MENGEL M, DOLLINGER M, et al. Prevention of rebleeding from esophageal varices in patients with cirrhosis receiving small-diameter stents versus hemodynamically controlled medical therapy[J]. Gastroenterology, 2015, 149(3): 660-668. e1. DOI: 10.1053/j.gastro.2015.05.011.
[35]	HOLSTER IL, TJWA ET, MOELKER A, et al. Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy+β-blocker for prevention of variceal rebleeding[J]. Hepatology, 2016, 63(2): 581-589. DOI: 10.1002/hep.28318.
[36]	LV Y, QI X, HE C, et al. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial[J]. Gut, 2018, 67(12): 2156-2168. DOI: 10.1136/gutjnl-2017-314634.
[37]	WANG Q, LV Y, BAI M, et al. Eight millimetre covered TIPS does not compromise shunt function but reduces hepatic encephalopathy in preventing variceal rebleeding[J]. J Hepatol, 2017, 67(3): 508-516. DOI: 10.1016/j.jhep.2017.05.006.
[38]	TREBICKA J, BASTGEN D, BYRTUS J, et al. Smaller-diameter covered transjugular intrahepatic portosystemic shunt stents are associated with increased survival[J]. Clin Gastroenterol Hepatol, 2019, 17(13): 2793-2799. e1. DOI: 10.1016/j.cgh.2019.03.042.
[39]	PRAKTIKNJO M, ABU-OMAR J, CHANG J, et al. Controlled underdilation using novel VIATORR^® controlled expansion stents improves survival after transjugular intrahepatic portosystemic shunt implantation[J]. JHEP Rep, 2021, 3(3): 100264. DOI: 10.1016/j.jhepr.2021.100264.
[40]	HE C, LV Y, WANG Z, et al. Association between non-variceal spontaneous portosystemic shunt and outcomes after TIPS in cirrhosis[J]. Dig Liver Dis, 2018, 50(12): 1315-1323. DOI: 10.1016/j.dld.2018.05.022.
[41]	LV Y, CHEN H, LUO B, et al. Concurrent large spontaneous portosystemic shunt embolization for the prevention of overt hepatic encephalopathy after TIPS: A randomized controlled trial[J]. Hepatology, 2022. DOI: 10.1002/hep.32453.[Online ahead of print]
[42]	BOIKE JR, THORNBURG BG, ASRANI SK, et al. North American practice-based recommendations for transjugular intrahepatic portosystemic shunts in portal hypertension[J]. Clin Gastroenterol Hepatol, 2021. DOI: 10.1016/j.cgh.2021.07.018.[Online ahead of print]
[43]	RÖSSLE M, SIEGERSTETTER V, OLSCHEWSKI M, et al. How much reduction in portal pressure is necessary to prevent variceal rebleeding? A longitudinal study in 225 patients with transjugular intrahepatic portosystemic shunts[J]. Am J Gastroenterol, 2001, 96(12): 3379-3383. DOI: 10.1111/j.1572-0241.2001.05340.x.
[44]	SILVA-JUNIOR G, TURON F, BAIGES A, et al. Timing affects measurement of portal pressure gradient after placement of transjugular intrahepatic portosystemic shunts in patients with portal hypertension[J]. Gastroenterology, 2017, 152(6): 1358-1365. DOI: 10.1053/j.gastro.2017.01.011.